Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.

ABSTRACT:

Background

Pulmonary sarcomatoid carcinomas (PSC) are notorious for their poor prognosis and resistance to chemotherapy. The literature suggests that immunotherapy might be effective against this aggressive tumor. This study aims to evaluate the efficacy of immunotherapy, either alone or combined with chemotherapy, as first-line treatment for PSC patients.

Methods

In a retrospective, multicentric, real-world study conducted between July 2017 and April 2021, patients with stage III (ineligible for surgery or radio-chemotherapy) or stage IV PSC were enrolled. These patients received their first-line treatment with immunotherapy and were categorized into two groups based on their treatment modality: the immuno-chemotherapy (IO CT) group or the immunotherapy-alone (IO) group.

SUBMITTER: Birsen G 

PROVIDER: S-EPMC11484717 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature